Mankind Pharma Expands Global Footprint with New Subsidiary in Sri Lanka

Mankind Pharma Ltd has announced the incorporation of a wholly owned subsidiary in Sri Lanka, marking a strategic leap into South Asia’s pharmaceutical and OTC markets. The move aligns with the company’s long-term vision to strengthen its international presence.

Key Highlights

- The subsidiary will be 100 percent owned by Mankind Pharma, either directly or through an intermediate holding.

- An investment of USD 350,000 (approximately Rs 2.99 crore) will be made in tranches, funded via internal accruals.

- The new entity will focus on import, trading, marketing, distribution, and contract manufacturing of pharmaceutical and consumer healthcare products.

Strategic Significance

- Sri Lanka is viewed as a gateway to emerging South Asian markets, offering growth potential in generics and wellness segments.

- The incorporation is subject to approvals from RBI, FEMA, and Sri Lankan regulatory bodies.

- The initiative is not a related party transaction and has been negotiated on an arm’s length basis.

Sources: Business Standard, MoneyWorks4Me, HDFC Sky, Chola Securities.